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Prostate Cancer Screening Trends After United States
Preventative Services Task Force Guidelines
in an Underserved Population
Neel H. Patel,1,* Jonathan Bloom,2 Joel Hillelsohn,1 Sean Fullerton,1 Denton Allman,1
Gerald Matthews,1 Majid Eshghi,1 and John L. Phillips1
Abstract
Purpose: Prostate cancer screening is a controversial topic. We examined trends in Prostate Speciﬁc Antigen
(PSA) testing in an underserved population before and after the United States Preventative Services Task
Force (USPSTF) recommendation against screening.
Methods: Data were collected on all PSA and cholesterol screening tests from 2008 to 2014. We examined the
trend of these tests and prostate biopsies while comparing this data to lipid panel data to adjust for changes in
patient population.
Results: A decrease in PSA screening was observed from 2010 through 2014, with the greatest decline in 2012.
The age group most affected was patients aged 55–69 years. The amount of prostate biopsies during this period
decreased as well.
Conclusions: Decreased rates of PSA screening were observed in our urban hospital population that preceded
the publication of the USPSTF guidelines. The incidence of prostate biopsies decreased in this timeframe. It now
remains to be demonstrated whether decreased PSA screening rates impact the diagnosis of and ultimately the
survival from prostate cancer.
Keywords: prostate biopsy; prostate cancer, Prostate Speciﬁc Antigen; urban health; USPSTF
Introduction
Prostate cancer is the second leading cause of cancer-
related death in men.1 Prostate Speciﬁc Antigen (PSA)
screening offers improved detection rates of prostate
cancer with the downside of overtreatment of low-risk
disease.2,3 Treatment is often associated with signiﬁcant
side effects causing a change in quality of life related to
urinary, sexual, and bowel function.4 Much of this mor-
bidity also stems from the overtreatment of very-low
and low-risk disease that may be better suited for active
surveillance (AS).5 AS has gained in popularity but is not
yet universally accepted by all who may beneﬁt.6
Two large but controversial randomized trials assessed
the impact of prostate cancer screening on mortality and
became the basis for recommendations by the United
States Preventative Services Task Force (USPSTF). The
Prostate, Lung, Colorectal and Ovarian (PLCO) trial
assigned over 75,000 men to annual PSA screening and
a similar self-reported ‘‘control’’ group who did not un-
dergo regimented PSA screening. PLCO reported no dif-
ference in cancer-speciﬁc mortality at 10 years between
the two groups.7 The control group of the PLCO trial ap-
pears to have actually undergone equal or more intense
PSA screening than the arm assigned to PSA testing.8
In contrast, the EuropeanRandomized Study of Screen-
ing for Prostate Cancer (ERSPC) evaluated over 160,000
men in multiple nations with different PSA screening ap-
proaches. The ERSPC demonstrated a 20% reduction in
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prostate cancer-speciﬁcmortality at amedian follow-up of
9years, butover 1400patientsneeded tobe screened topre-
vent one prostate cancer death.9 Based on the PLCO and
ERSPC ﬁndings, the USPSTF concluded that the harm
of PSA screening outweighed the beneﬁts and assigned
a grade D recommendation against screening in early
2012.10 After these guidelines were published, PSA screen-
ing remained controversial and individual screening prac-
tices have continued although highly varied.11,12 This is
due to physicians, medical bodies and patients already
established opinions regarding PSA screening.
After the USPSTF released this guideline, a survey of
men aged 40–74 years was conducted to assess PSA aware-
ness and men’s responses to it.11 Overall, 62% of men
agreed with the USPSTF grade D recommendation but
only 13% intended to decline PSA testing, while 54% pre-
ferred to obtain a PSA test. The American Urological
Association (AUA) guideline on early detection of prostate
cancer does not advise screening in men younger than 40
or older than 70 years, or those with less than a 10-year life
expectancy.13 The AUA and American Cancer Society
(ACS) currently recommend that PSA testing be offered
to asymptomatic men aged 55–69 years (AUA) or men
older than 50 years with a minimum 10-year life expec-
tancy (ACS) after patients receive information about the
harms and beneﬁts associated with screening.14
The AUA also reexamined their screening recom-
mendations during this time period and downgraded
their recommendation on PSA screening from an A
to an overall C with the caveat that men aged 55–69
should undergo ‘‘shared decision making’’ with their
physician concerning the potential harms and beneﬁts
of PSA screening.15 Currently, the USPTSF has now
released a preliminary grade C recommendation in
2017.16 The reasoning behind the upgrade in recom-
mendation was due to the ERSPC trial’s reported con-
tinued beneﬁt from screening in those aged 55–69, the
mitigated risk of overtreatment with increased use of
AS, and those most at risk for prostate cancer likely
beneﬁting from screening, namely African Americans
(AA) and men with a family history of disease. The re-
sult of the 2012 USPSTF recommendations is still being
assessed in terms of changes in PSA screening intensity,
and, ultimately, changes in prostate cancer speciﬁc-
related death. Houston et al., found a decreased overall
screening with a 7.5% reduction in the incidence of lo-
calized prostate cancer but a 1.4% increase in the inci-
dence of metastatic disease.17
The risk of death from prostate cancer varies among
different socioeconomic groups as higher socioeconomic
status has been associated with easier access to screen-
ing and ultimately biopsy and diagnosis.18 Additionally,
those without insurance, AA and Hispanic populations,
and lower socioeconomic status more often present at a
more advanced stage.19 While this may be due to a delay
in diagnosis, there is some evidence that AA men may
present with more aggressive disease as there is a higher
rate of upgrading at the time of radical prostatectomy
and higher rates of biochemical recurrence.20,21
In this study, we examined trends in PSA screening at
an urban hospital in a designated medically underserved
population with an increased incidence of prostate can-
cer of 21% compared with the general population.22–24
Methods
Patient data
After Internal Review Board approval, the number of
PSA and, as a control, lipid panel tests were recorded
for all patients by all providers, regardless of specialty,
in a public, urban community hospital from January
2008 to December 2014. We used the ICD 9 code
V76.44 or ‘‘screening for malignant neoplasms of pros-
tate’’ to populate a de-identiﬁed database, excluding pa-
tients who received PSA for monitoring prostate cancer
(ICD- 9 code 185). PSA screening tests were extracted
from the health system central laboratory, including
variables of month and year of service, PSA value, patient
age, and race. To provide adjustments for changes in pa-
tient population and practice, we compared the ratio of
number of PSA screening tests to lipid panel screening
tests done for male patients at our institution. Further-
more, we stratiﬁed the data into age ranges commonly
used for prostate cancer screening guidelines (<40, 40–
54, 55–69, ‡70) and performed subset analyses. Insur-
ance status were not available for these subjects, however,
this hospital is located in a New York State Department
of Health (DOH)-designated underserved area.
Prostate biopsy data from the same time period were
collected and analyzed to further assess the effect of
PSA screening on the use of diagnostic procedures.
Statistics
PSA and lipid panel screening cohorts were analyzed
using bivariate linear regression and subset analyses
were performed to evaluate for differential changes in
screening based on patient characteristics such as age
and use of prostate biopsy. Patient characteristics were
compared between the pre and post-USPSTF recom-
mendation cohorts. We compared PSA data against
lipid panel data to control for variations in population.
Patel, et al.; Health Equity 2018, 2.1
http://online.liebertpub.com/doi/10.1089/heq.2018.0004
56
Statistical testing was two-sided with a statistical signif-
icance set with an alpha of 0.05.
Results
A total of 16,333 PSA screening tests were performed
from January 2008 to December 2014 at the study in-
stitution that met the inclusion criteria. A monthly av-
erage of 194 – 92 PSA tests were performed compared
to 148,610 lipid panel tests in these men with a monthly
average of 2054– 247. Table 1 shows the demographic
data between between 2008 and 2014, where the mean
age of patients who had PSA screening performed was
66.4 and 62.2 years respectively. The breakdown by
race between 2008 and 2014 was 60% AA, 23% His-
panic, and 5% Caucasian versus 58% AA, 24% Hispanic,
and 5% Caucasian, respectively.
Figure 1 demonstrates the change in PSA screening at
our institution over the study period. PSA screening by
years shows that testing remained roughly stable from
2008 to 2009, but then began to decline in 2010 having
the largest change in 2012 (b=407.86, p= 0.001) with
a 29% decline. When analyzing these trends by month,
the similar change was still appreciated with the lowest
screening rates observed toward the end of the year
(b=3.01, p> 0.001).
As seen in Figure 2, we present the data for Lipid Panel
testing showing that there were no substantial changes
and screening remained relatively stable throughout the
study years (b= 37.89, p= 0.673). Likewise, the trend by
months shows similar changes (b=0.11, p= 0.922).
Subset analysis was also performed to further quan-
tify the USPSTF guideline changes on screening with
regards to age. Figure 3 demonstrates trends in PSA
screening along the following age groups: <40, 40–54,
55–69, and ‡70. Decrease in screening were noted in
all age groups except <40 years, which remained stable
Table 1. Demographic Information for Study Population
in 2008 and 2014
2008 2014 p
PSA screening (n) 3307 1234 —
Median age 66.4 62.2 < 0.001
Race (%)
African-American 60 58
Hispanic 23 24
Caucasian 5 5
Asian 2 2
Other 10 11
PSA, Prostate Speciﬁc Antigen.
FIG. 1. PSA tests ordered from 2008 to 2014 by months. PSA, Prostate Speciﬁc Antigen. b, slope; p, p-value.
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FIG. 3. PSA tests ordered from 2008 to 2014 by age stratiﬁcation. b, slope; p, p-value.
FIG. 2. Lipid panel tests ordered from 2008 to 2014 by months. b, slope; p, p-value.
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(b= 0.61, p= 0.730). The largest decline was noted in pa-
tients within the 55–69 age group, which also had the
highest number of PSA screening tests (b=173.32,
p< 0.001). Similar to the observed changes in PSA
screening, we also observed a decline in prostate biopsies
as shown in Figure 4 (b=10.04, p= 0.003). During this
time period, we observed a 73% decrease in the rate of
prostate biopsies.
Discussion
Less PSA screening may lead to missed opportunities
for detection of cancer at an early stage and preventing
death especially in groups at risk for aggressive prostate
cancer (e.g., AA men). The USPSTF grade D recom-
mendation against the screening of prostate cancer re-
leased in 2012 has led to major debates on how PSA
screening should and should not be done, how to better
diagnose prostate cancer, and determine which diag-
nosed cancers should be left untreated.25–27
Our investigation preceded the USPSTF report by
4 years and showed that a decline in PSA screening
began 2 years before the USPSTF guidelines were pub-
lished. In contrast, cholesterol screening with the use of
lipid panel testing demonstrated no change during the
study period suggesting that practitioners had main-
tained their interest in lipid panel testing while that in
PSA testing declined. Our results are in agreement with
Aslani et al., where they observed a decline in PSA
screening from March 2009 to May 2012 (b=0.001,
p<0.001), which was continued thereafter with the release
of the May 2012 USPSTF guidelines.25 The decrease that
was most pronounced in the 55–69 age group occurring 2
years before the USPSTF guidelines may be related to the
inﬂuence of the PCLO and ERSPC trials.28 This may re-
ﬂect ongoing attitudes with PSA screening early on, and
the decline noted in 2012 after the USPSTF guidelines
could stem from the continued decline as a result of the
PLCO and ERSPC trials, the 2012 USPSTF recommenda-
tion, a combination of the two, or other unknown factors.
It is also possible that this change in attitude before the re-
lease of the guidelines may have exacerbated the decline.
This study also demonstrated a decrease in PSA screen-
ing in all age groups except 40 years and younger, with the
largest decline in ages 55–69. Similarly, with other studies
this trend extended to patients of all ages, especially from
age 50 and above.25,27,29,30 These ﬁndings are in contrast
to current AUA guidelines, in which PSA testing should
be offered to patients age 55–69 after shared decision
making. The decline seen may be evidence of variation
in screening recommendations that preceded, but could
be further inﬂuenced by the USPSTF recommendations.
Our observations also highlight the importance of con-
sensus in the use of any screening test among practition-
ers from different specialties who all wish to optimize the
efﬁcacy and safety of early detection.31
In our study, our rate of biopsies decreased during
this time period. Prostate biopsies are generally safe
and informative, but do have reported morbidity rates
that include anxiety, infection, bleeding, pain, and sep-
sis.32 One of the perceived risks of PSA screening, there-
fore, has been requiring all men with an abnormal PSA
to undergo the risks of prostate biopsy even though the
FIG. 4. Prostate biopsies performed from 2008 to 2014. b, slope; p, p-value.
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majority of these men may have no cancer. Banerji et al.
noted that a decrease in prostate biopsies is associated
with a decrease in the detection of potentially curable
so-called ‘‘intermediate’’ risk cancer.33 Bhindi et al.
reviewed nearly 3400 prostate biopsies within the Univer-
sity Health Network of Toronto and also noted that PSA
and prostate biopsy rates decreased due to USPSTF rec-
ommendations and that the median number of interme-
diate and high grade prostate cancers diagnosed per
month decreased from 17.5 to 10.0 (p<0.001).34 Olsson
et al. demonstrated that after theUSPSTF guidelines, pros-
tate biopsies were associated with an increase in higher
risk features including a higher number of positive biopsy
cores and a greater incidence of high grade disease.35
These ﬁndings suggest that a downside of decreased
PSA screening is that patients may present with higher
risk disease and that the possible beneﬁts of reduced
PSA screening could be mitigated by an increase in
cancer-related morbidity and mortality.
The patient population of interest resideswithin aDOH
designated medically underserved area. Furthermore, be-
tween 2008 and 2014, over 80% of our patients have AA
or Hispanic backgrounds. This is in contrast to a rate of
13.3%AA and 17.8%Hispanic or LatinoAmericans resid-
ing in the United States, while over 70% are Caucasian.36
Despite trends and recommendations that may be appro-
priate for the general U.S. population, practitioners should
be mindful when dealing with a different patient compo-
sition, especially one that is at higher risk for prostate can-
cer. The AA and African-Caribbean populations have
shown to have up to 60% greater risk for prostate cancer
compared to Caucasian counterparts.37 Multifactorial rea-
sons may exist for the increased incidence due to race
such as genomic changes related to prostate cancer,
which are more common in these populations and in-
creased testosterone levels compared to other races.38,39
Our study was unique in focusing on the trends in a
cancer-screening test at an urban hospital in an under-
served population where the risk of prostate cancer is on
average higher than surrounding populations.22–24 Such
patients may be more adversely affected by declining
PSA screening than lower at-risk populations. Patients
with an AA and African-Caribbean ancestry, low socio-
economic status, lack of health insurance coverage, un-
equal access to healthcare services, and less continuity
with a primary care physician are all at risk of more ad-
vanced prostate cancer, trends that could worsen with
declining rates of early diagnosis.40
Limitations of our study include a retrospective study
design and limitation to a single institution in a highly
populated demographic area. Validation with larger co-
horts is needed. Comparison of PSA to lipid panel test-
ing to provide for changes in patient volume is an
adjustment that relies on providers and their practice
patterns that could not be further evaluated or con-
trolled. Similar to the study by Aslani et al., we believed
that our approach to screening tests would take routine
patient visits into account and be an appropriate mea-
sure of comparison.25
Conclusion
Our ﬁndings demonstrate a statistically signiﬁcant de-
crease in PSA screening and prostate biopsies within
an urban population that preceded national USPSTF
recommendations against PSA screening that are invari-
ably due to other factors besides the 2012 guidelines. It
is possible that the controversy surrounding the PSA
debate resulted in physicians more carefully selecting
patients for PSA screening. It is important that as
we screen fewer patients for prostate cancer we develop
strategies to continue making PSA screening available
for those most at risk, minority men and those with dif-
ﬁcult access to healthcare. Further studies are needed to
determine whether there is any additional prostate can-
cer mortality because of decreased screening and pros-
tate biopsies in these underserved populations and if
any of these trends are reversed with the recent reversal
in USPSTF recommendations.
Acknowledgments
We would like to thank New York Medical College and
Metropolitan Hospital for granting us the permission
to make this study possible.
Author Disclosure Statement
None of the contributing authors have any conﬂicts of
interest, including speciﬁc ﬁnancial interests or rela-
tionships and afﬁliations relevant to the subject matter
or materials discussed in the article.
References
1. Brawley OW. Prostate cancer epidemiology in the United States. World J
Urol. 2012;30:195–200.
2. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer
diagnosis in the eras before and after serum prostate-speciﬁc antigen
testing. JAMA. 1995;274:1445–1449.
3. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-
speciﬁc antigen screening: lessons from U.S. prostate cancer incidence
trends. J Natl Cancer Inst. 2002;94:981–990.
4. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction
with outcome among prostate-cancer survivors. N Engl J Med. 2008;
358:1250–1261.
5. National Comprehensive Cancer Network. Prostate Cancer (Version 2.2017).
https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
(Accessed October 4, 2017).
Patel, et al.; Health Equity 2018, 2.1
http://online.liebertpub.com/doi/10.1089/heq.2018.0004
60
6. Cooperberg MR, Carroll PR. Trends in management for patients with lo-
calized prostate cancer, 1990–2013. JAMA. 2015;314:80–82.
7. Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Mortality results from a ran-
domized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319.
8. Shoag JE, Mittal S, Hu JC. Reevaluating PSA Testing Rates in the PLCO
Trial. N Engl J Med. 2016;374:1795–1796.
9. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-
cancer mortality in a randomized European study. N Engl J Med. 2009;
360:1320–1328.
10. Moyer VA, Force USPST. Screening for prostate cancer: U.S. Preventive
Services Task Force recommendation statement. Ann Intern Med. 2012;
157:120–134.
11. Squiers LB, Bann CM, Dolina SE, et al. Prostate-speciﬁc antigen testing:
men’s responses to 2012 recommendation against screening. Am J Prev
Med. 2013;45:182–189.
12. Hutchinson R, Akhtar A, Haridas J, et al. Testing and referral patterns in the
years surrounding the US Preventive Services Task Force recommendation
against prostate-speciﬁc antigen screening. Cancer. 2016;122:3785–3793.
13. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer:
AUA Guideline. J Urol. 2013;190:419–426.
14. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline
for the early detection of prostate cancer: update 2010. CA Cancer J Clin.
2010;60:70–98.
15. Loeb S. Guideline of guidelines: prostate cancer screening. BJU Int. 2014;
114:323–325.
16. Bibbins-Domingo K, Grossman DC, Curry SJ. The US Preventive Services
Task Force 2017 draft recommendation statement on screening for pros-
tate cancer: an invitation to review and comment. JAMA. 2017;317:1949–
1950.
17. Houston KA, King J, Li J, et al. Trends in prostate cancer incidence rates
and prevalence of prostate-speciﬁc antigen screening by socioeconomic
status and regions in the US, 2004–2013. J Urol. [Epub ahead of print]
DOI: 10.1016/j.juro.2017.09.103.
18. Rundle A, Neckerman KM, Sheehan D, et al. A prospective study of socio-
economic status, prostate cancer screening and incidence among men at
high risk for prostate cancer. Cancer Causes Control. 2013;24:297–303.
19. Weiner AB, Matulewicz RS, Tosoian JJ, et al. The effect of socioeconomic
status, race, and insurance type on newly diagnosed metastatic prostate
cancer in the United States (2004–2013). Urol Oncol. 2018;36:91.e1–91.e6.
20. Freedland SJ, Vidal AC, Howard LE, et al. Race and risk of metastases and
survival after radical prostatectomy: results from the SEARCH database.
Cancer. 2017;123:4199–4206.
21. Maurice MJ, Sundi D, Schaeffer EM, et al. Risk of pathological upgrading and
up staging among men with low risk prostate cancer varies by race: results
from the national cancer database. J Urol. 2017;197(3 Pt 1):627–631.
22. Services USDoHaH. Medically Underserved Areas Database- Health
Resources and Service Administration Data Warehouse. 2016. Available at
www.datawarehouse.hrsa.gov (Accessed October 4, 2017).
23. Health NYSDo. Cancer Incidence for East Harlem Neighborhood, Man-
hattan 2008–2012. 2014. Available at www.health.ny.gov/statistics/
cancer/registry/vol1/v1neastharlem.htm (Accessed October 4, 2017).
24. Surveillance E, and End Results (SEER) Program SEER*Stat Database:
Table 23.7–Cancer of the Prostate (Invasive)–SEER Incidence and US Death
Rates, Age-Adjusted and Age-Speciﬁc Rates (2008–2012). 2012, 2016.
25. Aslani A, Minnillo BJ, Johnson B, et al. The impact of recent screening
recommendations on prostate cancer screening in a large healthcare
system. J Urol. 2014;191:1737–1742.
26. Barocas DA, Mallin K, Graves AJ, et al. Effect of the USPSTF Grade D rec-
ommendation against screening for prostate cancer on incident prostate
cancer diagnoses in the United States. J Urol. 2015;194:1587–1593.
27. Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing
patterns in relation to USPSTF screening recommendations. JAMA. 2015;
314:2054–2061.
28. Cohn JA, Wang CE, Lakeman JC, et al. Primary care physician PSA
screening practices before and after the ﬁnal U.S. Preventive
Services Task Force recommendation. Urol Oncol. 2014;32:41 e23–e30.
29. Li J, Berkowitz Z, Hall IJ. Decrease in prostate cancer testing following the
US Preventive Services Task Force (USPSTF) recommendations. J Am
Board Fam Med. 2015;28:491–493.
30. Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates
after the 2012 US Preventive Services Task Force recommendation dis-
couraging prostate-speciﬁc antigen-based screening. J Clin Oncol. 2015;
33:2416–2423.
31. Cooperberg MR. Implications of the new AUA guidelines on prostate
cancer detection in the U.S. Curr Urol Rep. 2014;15:420.
32. Efesoy O, Bozlu M, Cayan S, et al. Complications of transrectal ultrasound-
guided 12-core prostate biopsy: a single center experience with 2049
patients. Turk J Urol. 2013;39:6–11.
33. Banerji JS, Wolff EM,Massman JD, 3rd,et al. Prostate needle biopsy outcomes
in the era of the U.S. Preventive Services Task Force recommendation
against Prostate Speciﬁc Antigen based screening. J Urol. 2016;195:66–73.
34. Bhindi B, Mamdani M, Kulkarni GS, et al. Impact of the U.S. Preventive Services
Task Force recommendations against Prostate Speciﬁc Antigen screening on
prostate biopsy and cancer detection rates. J Urol. 2015;193:1519–1524.
35. Olsson CA, Anderson AE, Kapoor DA. Trends in histology of newly diag-
nosed prostate cancer subsequent to USPSTF PSA screening recommen-
dation. 2016 Genitourinary Cancers Symposium; January 7–9, 2016, 2016.
36. US Census Quick Facts. 2016–2017. Available at www.census.gov/
quickfacts/fact/table/US/PST045217 (Accessed February 10, 2018).
37. Thakare N, Chinegwundoh F. Prostate cancer in the African-Caribbean
community. Trends Urol Mens Health. 2015;6:32–35.
38. Freedman ML, Haiman CA, Patterson N, et al. Admixture mapping iden-
tiﬁes 8q24 as a prostate cancer risk locus in African-American men. Proc
Natl Acad Sci U S A. 2006;103:14068–14073.
39. Wu AH, Whittemore AS, Kolonel LN, et al. Serum androgens and sex
hormone-binding globulins in relation to lifestyle factors in older African-
American, white, and Asian men in the United States and Canada. Cancer
Epidemiol Biomarkers Prev. 1995;4:735–741.
40. Talcott JA, Spain P, Clark JA, et al. Hidden barriers between knowledge
and behavior: the North Carolina prostate cancer screening and treat-
ment experience. Cancer. 2007;109:1599–1606.
Cite this article as: Patel NH, Bloom J, Hillelsohn J, Fullerton S, Allman
D, Matthews G, Eshghi M, Phillips JL (2018) Prostate cancer screening
trends after United States Preventative Services Task Force Guidelines
in an underserved population, Health Equity 2:1, 55–61,
DOI: 10.1089/heq.2018.0004.
Abbreviations Used
AA¼African Americans
ACS¼American Cancer Society
AS¼ active surveillance
AUA¼American Urological Association
DOH¼Department of Health
ERSPC¼ European Randomized Study of Screening for Prostate
Cancer
PLCO¼ Prostate, Lung Colorectal and Ovarian
PSA¼ Prostate Speciﬁc Antigen
USPSTF¼United States Preventative Services Task Force
Publish in Health Equity
- Immediate, unrestricted online access
-Rigorous peer review
-Compliance with open access mandates
-Authors retain copyright
-Highly indexed
-Targeted email marketing
liebertpub.com/heq
Patel, et al.; Health Equity 2018, 2.1
http://online.liebertpub.com/doi/10.1089/heq.2018.0004
61
